David Mutch
SPORE in Endometrial Cancer Core Lead · Washington University/B-JH/SLCH Consortium
Credentials: · · ·
History
Research
New England Journal of Medicine · 1999 · Last of 9 authors · 1,758 citations
FIGO staging of endometrial cancer: 2023
International Journal of Gynecology & Obstetrics · 2023 · 869 citations
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 840 citations
195 papers · 49 as a fellow
100 papers · 4 as a fellow
86 papers · 9 as a fellow
70 papers · 15 as a resident
69 papers · 16 as a fellow
Perry Grigsby
59 papers
- SM
55 papers · 9 as a resident
50 papers · 29 as a resident
Grants
- 2023–2028
Route 66 Endometrial Cancer SPORE
National Cancer Institute · P50
Contact PI · $9.9M · Washington University
- 2014–2021
Integrated Translational Genoproteomics Center at Washington University
National Cancer Institute · U10
Contact PI · $2.6M · Washington University
- 2014–2019
Washington University/ Siteman Cancer Center Lead Academic Site
National Cancer Institute · U10
PI · $7.6M · Washington University
- 2009–2014
National Cancer Institute · P50
Contact PI · $847.9K · Washington University
Clinical trials
- 2025–2035
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Principal investigator · Recruiting · Phase 1
Washington University School of Medicine
- 2024–2034
AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer
Principal investigator · Withdrawn · Phase 1
Washington University School of Medicine
- 2008–2012
Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma
Principal investigator · Completed · Phase 2
Washington University School of Medicine
- 2007–2012
Topotecan, Cisplatin and Bevacizumab for Recurrent/Persistent Cervical Cancer
Principal investigator · Completed · Phase 2
Washington University School of Medicine